Conversely, the CREATE-X trial [15] randomly assigning 910 patients with residual disease after NAC to receive postsurgical treatment (radiotherapy +/- hormone therapy when indicated) either with or without Capecitabine showed that adjuvant Capecitabine significantly improved DFS and OS rates in HER2-negative BC. Here, ERBB2 is linked to breast cancer.